RNAi therapeutics company Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) appointed Margaret Hamburg to its board, effective Jan. 10, 2019. Hamburg is president-elect of the American Association for the Advancement of Science (AAAS), foreign secretary of the National...

Regenerative biomaterial company PolarityTE Inc. (NASDAQ:COOL) terminated Chief Investment Officer and EVP John Stetson on Friday after the Securities and Exchanges Commission filed charges against him alleging his involvement in "pump-and-dump" schemes (see "Opko's Frost...

Cancer company Verastem Inc. (NASDAQ:VSTM) named NgocDiep Le CMO. She was VP of immuno-oncology innovative medicines at the MedImmune LLC subsidiary of AstraZeneca plc (LSE:AZN; NYSE:AZN). Rare disease company OxThera AB (Stockholm, Sweden) named Bastian...

Immunotherapy company Advaxis Inc. (NASDAQ:ADXS) said President and CEO Daniel O’Connor resigned. CBO Anthony Lombardo will be interim CEO while the company seeks a replacement. Rare disease company OxThera AB (Stockholm, Sweden) named Matthew Gantz...

OxThera raised €32 million ($34.1 million) in a round co-led by LSP, Ysios Capital, Sunstone Capital and Flerie Invest. Existing investors Kurma Partners, Idinvest Partners, Stiftelsen Industrifonden and Brohuvudet also participated. OxThera AB , Uppsala, Sweden ...

OxThera AB (Uppsala, Sweden) raised EUR 32 million ($34.1 million) in a round co-led by LSP, Ysios Capital, Sunstone Capital and Flerie Invest. Also participating were existing investors Kurma Partners, Idinvest Partners, Stiftelsen Industrifonden and...

The European Commission granted Orphan Drug designation to Oxabact from OxThera to treat short bowel syndrome (SBS). The capsule formulation of lyophilized live Oxalobacter formigenes has Orphan Drug designation in the EU and U.S. to...

OxThera AB , Uppsala, Sweden   Business: Endocrine/Metabolic   Date completed: 4/16/14   Type: Venture financing   Raised: SEK70 million ($10.7 million)   Investors: Kurma Partners; Idinvest Partners; Mayo Clinic ; existing investors  ...

OxThera AB , Uppsala, Sweden   Business: Endocrine/Metabolic   Appointed: Georges Gemayel as chairman  ...

OxThera began the double-blind, placebo-controlled, European Phase I/II OC5-DB-01 trial to evaluate twice-daily oral Oxabact in 24 patients with primary hyperoxaluria. Oxabact has Orphan Drug designation for the indication in the EU and U.S. OxThera...